Aurobindo Pharma Limited — JV/Acquisition, 23-07-2026: Acquisition

Aurobindo Pharma's subsidiary, Apitoria Pharma, is acquiring an 80% stake in A1 Biochem Group's Contract Research Services (CRO) business for an enterprise value of $17 million. This strategic move expands Aurobindo's presence in the API lifecycle, creating a dedicated Contract Research, Development, and Manufacturing (CRDMO) platform. It broadens the portfolio for full-service customer engagement and complements existing API manufacturing. A1 Biochem, with labs in USA and India, generated a turnover of INR 102.44 Cr and EBITDA of INR 46.55 Cr in FY2025-26, bringing an established client base and R&D capabilities. This acquisition strengthens Aurobindo's integrated offerings.